89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia-Reference-Cited by-同舟云学术

89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia

Published:2024-07-11 Issue: Volume: Page:
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Herrero Alvarez Natalia,Molvi Zaki,Lupo Kyle,Urraca Jessica,Balderes Paul,Nyakatura Elisabeth K.,Khan Abdul G.,Viray Tara,Lewis Jason S.^ORCID,O’Reilly Richard J.

Funder

NIH

Steven A. Greenberg Lymphoma Research Award

Alex's Lemonade Stand Foundation for Childhood Cancer

Richard “Rick” J. Eisemann Pediatric Research Fund

Tow Foundation

The Aubrey Found

Edith Robertson Foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06814-7.pdf

Reference43 articles.

1. Duval M, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–8. https://doi.org/10.1200/JCO.2010.28.8852.

2. Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 2017;52(8):1083–90. https://doi.org/10.1038/bmt.2017.8.

3. Campana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013;162(2):147–61. https://doi.org/10.1111/bjh.12358.

4. Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110–6. https://doi.org/10.1200/JCO.2005.09.133.

5. Caron P, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83(7):1760–8. https://doi.org/10.1182/blood.V83.7.1760.1760.